Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
It unifies complementary agentsshort-acting, long-acting, and regenerativeenabling broader, more sustained responses than single-peptide models
The risk of reduced potency or contamination is not worth the savings from squeezing out a few extra doses
Additionally, I test CTCs against oncology drugs, repurposed medicines, and naturopathic compounds to identify the most effective treatments
